Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 9/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.38 |
| ▸ | TACR2 | P21452 | 3/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5944653 | 0.79 | ACHE (0.38) | ALDH1A1MAPTACHECYP1A2TDP1 | |
| SCHEMBL5944502 | 0.76 | APOBEC3A (0.40) | CHRM1KMT2ATP53CHRM3ACHE | |
| SCHEMBL2486360 | 0.74 | ACHE (0.31) | ACHEOPRM1TSHRSMN1; SMN2BLM | |
| SCHEMBL15293598 | 0.71 | APOBEC3A (0.40) | CHRM1KMT2ATP53CHRM3ACHE | |
| SCHEMBL26422119 | 0.71 | ACHE (0.42) | ESR1ESR2ALDH1A1ADORA3SLC6A2 | |
| Hydroquinone SCHEMBL8441656 | 0.71 | LMNA (0.61) | ESR1ESR2ALDH1A1ADORA3SLC6A2 | |
| SCHEMBL31325824 | 0.70 | FNTA (0.44) | ESR1ESR2ALDH1A1ADORA3SLC6A2 | |
| Hydroquinone SCHEMBL3095350 | 0.68 | LMNA (0.67) | ESR1ESR2ALDH1A1ADORA3SLC6A2 | |
| Hydroquinone SCHEMBL6071932 | 0.68 | LMNA (0.67) | ESR1ESR2ALDH1A1ADORA3SLC6A2 | |
| Hydroquinone SCHEMBL11180188 | 0.68 | LMNA (0.67) | ESR1ESR2ALDH1A1ADORA3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579871-B2 | Phenyl oxazoles or thiazoles | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | PANETTA JILL ANN (US) | 2003-03-13 | — | — | US | disclosed |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | PANETTA JILL ANN (US) | 2002-11-28 | — | — | US | disclosed |
| US-6472387-B1 | Methods of using compounds as neuro-protective agents | ELI LILLY AND COMPANY | 2002-10-29 | — | — | US | disclosed |
| US-6448396-B2 | 2-((3,5-DIALKYL-4-HYDROXYPHENYL-4-(2-(AMINOALKYLPHENOXY)ETHYL) OXAZOLES; ANTIISCHEMIC AGENTS; REPERFUSION INJURY OF PERIPHERAL ORGANS; FREE RADICAL ANTAGONISTS; PARKINSON'S AND ALZHEIMER'S DISESES; DOWN'S SYNDROME; AMYOTROPHIC LATERAL S. | ELI LILLY AND COMPANY | 2002-09-10 | — | — | US | disclosed |
| US-6423709-B1 | FOR THERAPY OF ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, AMYTROPHIC LATERAL SCLEROSIS OR CEREBRAL TRAUMA IN A MAMMAL | ELI LILLY AND COMPANY | 2002-07-23 | — | — | US | disclosed |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | PANETTA JILL ANN (US) | 2002-05-30 | — | — | US | disclosed |
| US-6380213-B1 | PHENYL OXAZOLES, THIAZOLES, OXAZOLINES, OXADIAZOLES AND BENZOXAZOLES | ELI LILLY AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY | 2001-10-04 | — | — | US | disclosed |
| US-6166216-A | Compounds useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 2000-12-26 | — | — | US | disclosed |
| US-6156748-A | Compounds useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 2000-12-05 | — | — | US | disclosed |
| WO-1999018091-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | ELI LILLY AND COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
| EP-0908454-A2 | Oxazoles, thiazoles, oxazolines, oxadiazoles and benzoxazoles useful as neuro-protective agents | ELI LILLY AND COMPANY (US) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010027194-A1 | NOVEL COMPOUNDS USEFUL AS NEURO-PROTECTIVE AGENTS | NLN, PRDX5, TXN2 | ESR1 4584/4885ESR2 2158/4885ALDH1A1 1209/4885 |
| US-20020177595-A1 | Novel compounds useful as neuro-protective agents | NLN, PRDX5, TXN2 | ESR1 4584/4885ESR2 2158/4885ALDH1A1 1209/4885 |
| US-20020065274-A1 | METHODS OF USING NOVEL COMPOUNDS AS NEURO-PROTECTIVE AGENTS | NLN, GAP43, TXN2 | ESR1 4778/4885ESR2 2585/4885ALDH1A1 1309/4885 |
| US-20030050311-A1 | Methods of using novel compounds as neuro-protective agents | NLN, GAP43, TXN2 | ESR1 4778/4885ESR2 2585/4885ALDH1A1 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.